Effects of l-carnitine on dyslipidemia and anemia in hemodialysis patients

Subject Areas : علوم پزشکی

Mohammad Bagher Najjar Zadeh ¹ ( )
Maedeh Sadeghi Naeini pour ² ( )
Mahmud reza Khazaei ³ ( )

Received: 2017-06-06 Accepted : 2017-06-06 Published : 2012-11-21

Keywords: L-Carnitin, dyslipidemia, Anemia, hemodialys, chronic RenalFailure (CRF),

Abstract :

Introduction In patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia and anemia in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles and anemia in hemodialysis patients. Methods and Materials Thisrandomized clinical trialwas performedon patients undergoing continuous hemodialysis. Of 63 hemodialysis patientswere studied, 30 patients inthe control groupand 33 casesres pectively. The case group were treated for 6 months with oral L-carnitine (250 mg threetimes daily). At the beginning andthe end of thestudy, hemoglobin, triglycerides, total cholesterol, LDL, HDL, VLDL, albumin, KT / v, height, weight, BMI was measured. And withthe Demographic characteristics questionnaires were collected. Data collected by the spssv20 software  and other Statistical Methods descriptive and analytical  were evaluated. Results  There was no  significant changes in hemoglobin levels between the two groups. Compared between the 2 groups in terms of changes in lipid profile seems this medicine is not very effective in modifying lipid profiles, although slight and positive changes in lipid profile in Group (cases)  were found. The drugcauseda significant reductioninbody weight.And the mean BMI was significantly reduced in the cases group than the control group. Significant differences between the two groups in terms of changes in albumin is not found . Conclusion It seems to correct anemia and hyperlipidemia medication use carnitine is not effective in hemodialysis patients. However, use of this medication is effective in reducing the patient's weight loss and BMI.    

References:

 

 

1)       Thomas S, Fischer F, Mettang T, Pauli-Magnus C, Weber J, KuhlmannV. Effects of Lcarnitine on leukocyte function and viability in Hemodialysis patients;A double- blind randomized trial. AmJ Kiney Dis. 1999;34:678-87.

2)       Massry SG, Classock RJ . Massry & Glassoch.s Text book of nephrology. Philadelphia: LWW ; 2001.

3)       ArduiniA, Bonomini M, Savica V, Amato A, Zammit V. Carnitine in metabolic disease : Potential for pharmacological intervention. Pharmacol Ther 2008; 120 (2):149-56.

4)       Khazai M, Drakhshan A. Effects of l-carnitine orally in children undergoing chronic hemodialysis patients with hyperlipidemia. 56-49: (91)49 ;1385.

5)       Golper Thomas A, Goral S, Becker Bryan N, Langman Craig B . Review L-carnitine treatment of anemia. Am J Kidney Dis 2003, 4: 27-34.

6)       Shorecki K, Green J, Brenner BM. Chronic renal failure. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds). Harrison’s Principles of Internal Medicine. 18th ed. New York : McGraw-Hill; 2012: 1653-1663 .

7)       Singh SK, Brenner BM. Dialysis in the treatment of renal failure. In: Braunwald E, Fauci AS, Kasper DL, Hauser  SL, Longo DL, Jameson JL ,editors. Harrison ’s Principle of Internal Medicine. 18th ed. New York: McGraw-Hill; 2012:1560-1576

8)       Daugirdas J, Van Ston . Hemodialysis . In:Daugirdas J ,Blake P , Ing TS. Hand book of dialysis. 4^th ed . Philadelphia: Lippincott Williams & Wilkins; 2007.P.15-277.

9)       Chertow GM,Plone M,Dillon MA.Hyperparathyroidism and dialysis. Vintage clin nephrol. 2000;54(4):295-300.

10)    Coen G,Mazzaferro ,S. Bone metabolism and its assessment in renal failure. Nephron. 1994;67(3):383-401.

11)    Ahmad M, Robert R, Bargman JM,Oreopoulos D. Advantaages of peritoneal dialysis in comparison to hemodialysis, in cardiac allograft recipients with end stage renal disease. Int Urol Nephrol . 2008; 40(4): 1083-7.

12)    Goodman WG, Goldin J,Kuizon BD, Yoon C, Gales B,Sider D , Wang Y , Chung J , Emerick A,Greaser L , Elashoff RM , Salusky IB. Coronary-artery calcificationin young adults with end-stage renal disease who are undergoing dialysis. N Engl  J Med.2000;342(20):1478-83.

13)    Staly M.Peritoneal dialysis versus haemodialysis .Nephrology. 2010; 15(2):S24-S31.

14)    Libby P,Bonon RO,Maun DL, Zipes DP. Branunwalds Heart diseases:A Textbook of cardiovascular medicine. 7^th ed. New York: saunders ; 2007. P. 252-253,2286-2287.

15)    Braunword E. Harrison's Principle's of Internal Medicine. 18^th ed. New York, Mc Gram Hill, 2012; PP: 1761-1771.

16)    Braunword E. Harrison's Principle's of Internal Medicine. 18th ed. New York, Mc Gram Hill, 2012; PP: 2535-2536.

17)    Nejat shokouhi A.a review of biochemistry.3^th ed.mashhad: entesharate 59; 2006. 149-163.

18)    Brenner BM,Rector FC. Brenner & Rector's the Kidney. 8^th ed. Philadelphia: Saunders Elsevier; 2008.1889-1893

19)    Braunword E. Harrison's Principle's of Internal Medicine. 18th ed. New York, Mc Gram Hill, 2012; PP: 2131-2140

20)    Bloch AS, Shils ME. Appendices. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ(eds). Modern Nutrition in Health and Disease. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2006: 1896.

21)    Shahraz S, Ghaziani T. Iran pharma text book.2^th ed. Tehran: tabib; 2012.194.

22)    Naini AE, Moradi m, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, Basir Ghafoori H, Emami Naini P. Effects of oral l-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: a randomized , double- blinded, placebo-controlled trial. J nutr metab. 2012 jun; 22(5):6-7.

23)     NainiAE ,  Sadeghi M  , MortazaviM ,  Moghadasi M ,  Harandi A A. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. Saudi J Kidney Dis Transpl.2012 may ; 23 (3):484-8.

24)     Suchitra MM ,  Ashalatha VL ,  Sailaja E ,  Rao  AM,  Reddy VS ,  Bitla AR , Sivakumar V,  Rao  PV. The effect of L-Carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl. 2011 NOV; 22(6) : 1155-9.

25)     Sabry AA. The role of oral L-Carnitine therapy in chronic hemodialysis patients. Saudi J Kidney Dis Transpl.2010 may; 21(3):454-9.

26)    Wanic-Kossowska M, Kazmierski M, Pawliczak E, Kobelski M. Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis.pol arch med wewn  2007 ; 117 (1-2):14-19.

27)    Kadiroglu AK, Yilmaz ME ,Sit D , kara IH ,Isikoglu B.The evaluation of post dialysis l-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.ren fail 2005;27(4):367-372

28)    Satoshi Odo, Koji Tanabe, Masamitsu Yamauchi.  A Pilot Clinical Trial on L-Carnitine Supplementation in Combination with Motivation Training: Effects on Weight Management in Healthy Volunteers . Food and Nutrition Sciences. 2013 February;4(2):222-231.

29)    Evans A. Dialysis-related carnitine disorders and levocarnitine pharmacology. Am J Kidney Dis. 2003; [suppl.4]: S13-S26.

30)     Alberty R, Albertyova D. Biological variation of free and total carnitine in serum of healthy subjects. Clin Chem. 1997; 43: 2441-2443.

31)     Hoppel C. The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis. 2003; [suppl.4]: S4-S12.

32)     Guarnieri G, Biolo G, Toigo G, Situlin R. Carnitine in renal failure. In: Kopple JD, Massry SG (eds). Kopple and Massry's Nutritional Management of Renal Disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004: 357-368.

33)    National kidney foundation, kidney disease outcomes quality initiative. Clinical practice guidelines for anemia of chronic kidney disease, 2000:21.

34)     Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effect of recombinant erythropoietin. Kidney Int 1989; 35:134-148.

35)    Parker PA, Izard MW, Maher JF. Therapy of iron deficiency anemia in patients on maintenance dialysis.Nephron 1979; 23:181-186.

36)    Tacob HJ, Eaton JW, Yawata NY. Shortened blood cell survival in uremic patients, Beneficial and deleterious effects of dialysis. Kidney Int 1975; 7:139-143.

37)    Rosen kranz AR, Templ E,Traindl O, Hinzl H, Ziabinger GJ. Reachve oxygen produet foimation by human neturophils as an eary marker for biocompatibility of dialysis membranes .Clin EXP immurol 1994; 98:300-305.

38)    Bossola M, Muscaritoli M, Tazza L, Giungi S, Tortorelli A, Rossi FF, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46(3): 371-86.

39)    Retter AS. Carnitine and its role in cardiovasculardisease. Heart Dis 1999; 1(2): 108-13.

40)    Sarvghadi F, Rambod M, Hosseinpanah F, Hedayati M,Tohidi M, Azizi F. Prevalence of obesity in subjectsaged 50years and over in Tehran. Iranian Journal ofEendocrinology and Metabolism 2007; 2:99-104. [Farsi]

41)     Janghorbani M, Amini M, Willett W, Gouya M, DelavariA, Alikhani S, et al. First nationwide survey of prevalenceof overweight, underweight, and abdominalobesity in Iranian adults. Obesity (Silver Spring) 2007;15: 2797-808.

42)    Stephens F, Constantin-Teodosiu D, Greenhaff PL. Newinsights concerning the role of carnitine in the regulationoffuel metabolism in skeletal muscle. J Physiol 2007;581: 431-44.